Nancy Miller-Rich Acquires Shares of 4D Molecular Therapeutics

Nancy Miller-Rich recently bought 50,000 shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) on June 17, 2026. The stock was trading at $9.42 at the time of the transaction. This insider purchase adds to the company's ownership by its key stakeholders.

Insider Buying and Selling at 4D Molecular Therapeutics, Inc.

Alongside Nancy Miller-Rich, several other insiders acquired shares on the same day. Charles Theuer, Glenn Sblendorio, Susannah Gray, Jacob Chacko, and John Milligan also purchased 50,000 shares each, with Milligan acquiring 75,000 shares. None of these transactions were part of a pre-planned trading program, suggesting a direct endorsement of the company's prospects.

Other Institutional Activity in 4D Molecular Therapeutics

Institutional investors have shown varied interest in 4D Molecular Therapeutics. Janus Henderson Group PLC increased its holdings by 611,276 shares, reaching a total of 5,247,151 shares valued at about $48.87 million. In contrast, RA Capital Management, L.P. reduced its stake by 603,432 shares, holding 5,049,779 shares worth approximately $47.01 million. Meanwhile, Goldman Sachs Group Inc. trimmed its position by 97,467 shares, now owning 4,205,438 shares valued at $39.15 million. BlackRock, Inc. added 80,427 shares, holding 4,145,303 shares worth $38.59 million.

4D Molecular Therapeutics Stock Snapshot

Shares of 4D Molecular Therapeutics are trading near $9.42, with a market cap of roughly $505 million. The company is not currently profitable, so it has no meaningful P/E ratio. The stock has a beta of 2.756, indicating higher volatility compared to the market. Its 52-week range is between $3.68 and $12.34, with a 50-day moving average of $9.43 and a 200-day moving average of $9.24. The company's current ratio is 9.34, and its debt-to-equity ratio stands at 4.55.

Recent Earnings

In its latest earnings report, 4D Molecular Therapeutics posted revenue of $88.24 million, marking a significant growth of 216.64%. However, the company reported a net margin of -182.34% and a return on equity of -34.92%. The next earnings announcement is scheduled for August 10, 2026.

Analysts Set New Price Targets

Analysts have been optimistic about 4D Molecular Therapeutics. On March 30, 2026, Jefferies assumed coverage with a 'buy' rating and a $21 price target. HC Wainwright & Co. reiterated their 'buy' rating on March 20, 2026, with a target of $36. RBC Capital maintained their 'buy' rating on March 19, 2026, setting a target price of $35. Overall, the stock has a consensus 'buy' rating, with an average target price of $28.22 from nine analysts.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc. is a biotechnology company based in Emeryville, California. It focuses on developing adeno-associated virus vectors through its proprietary platform, Therapeutic Vector Evolution. The company's leading product candidate, 4D-150, targets retinal vascular diseases. Other products in development include 4D-710 for cystic fibrosis, 4D-175 for geographic atrophy, and 4D-725 for alpha-1 anti-trypsin deficiency lung disease. The company collaborates with Otsuka Pharmaceutical Co., Ltd.

Bottom Line

The recent insider buying at 4D Molecular Therapeutics signals confidence among its executives. While the company is not yet profitable, its innovative pipeline and robust revenue growth attract attention. Investors and analysts continue to watch this biotech firm closely, as evidenced by its positive analyst ratings and institutional interest. As always, it's important to remember that insider transactions and 13F filings reflect past actions and may not indicate future performance.